000 01198 a2200361 4500
005 20250517161710.0
264 0 _c20190319
008 201903s 0 0 eng d
022 _a1365-2133
024 7 _a10.1111/bjd.15755
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aRicceri, F
245 0 0 _aClinical experience with infliximab biosimilar in psoriasis.
_h[electronic resource]
260 _bThe British journal of dermatology
_c12 2017
300 _ae347-e348 p.
_bdigital
500 _aPublication Type: Letter
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aBiosimilar Pharmaceuticals
_xtherapeutic use
650 0 4 _aDermatologic Agents
_xtherapeutic use
650 0 4 _aDrug Substitution
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aInfliximab
_xtherapeutic use
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aPsoriasis
_xdrug therapy
650 0 4 _aTreatment Outcome
700 1 _aPescitelli, L
700 1 _aLazzeri, L
700 1 _aPrignano, F
773 0 _tThe British journal of dermatology
_gvol. 177
_gno. 6
_gp. e347-e348
856 4 0 _uhttps://doi.org/10.1111/bjd.15755
_zAvailable from publisher's website
999 _c27308571
_d27308571